Serum Institute starts manufacturing Codagenix's potential Covid-19 vaccine


(Reuters) - Codagenix Inc said on Tuesday Serum Institute of India has started manufacturing the U.S.

biotech firm's potential COVID-19 vaccine and it expects to begin early-stage human trial of the vaccine by the end of 2020 in the UK. Serum Institute, the world's largest vaccine maker by number of doses produced, will develop Codagenix's CDX-005, which is delivered intranasally rather than via an injection. Serum Institute is working on several vaccine candidates for the novel coronavirus - including potentially mass-producing.....

This article is no longer available in our repository.

There could be multiple reasons for this.